Tredje AP fonden Purchases 4,078 Shares of BioMarin Pharmaceutical Inc. $BMRN

Tredje AP fonden boosted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 290,742 shares of the biotechnology company’s stock after acquiring an additional 4,078 shares during the period. Tredje AP fonden owned 0.15% of BioMarin Pharmaceutical worth $15,982,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Byrne Financial Freedom LLC boosted its holdings in BioMarin Pharmaceutical by 4.4% in the first quarter. Byrne Financial Freedom LLC now owns 3,852 shares of the biotechnology company’s stock worth $272,000 after acquiring an additional 161 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its holdings in BioMarin Pharmaceutical by 0.9% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 22,523 shares of the biotechnology company’s stock worth $1,592,000 after acquiring an additional 197 shares in the last quarter. Securian Asset Management Inc. raised its stake in shares of BioMarin Pharmaceutical by 1.4% in the second quarter. Securian Asset Management Inc. now owns 14,604 shares of the biotechnology company’s stock worth $803,000 after purchasing an additional 197 shares during the last quarter. Xponance Inc. raised its stake in shares of BioMarin Pharmaceutical by 0.6% in the first quarter. Xponance Inc. now owns 31,877 shares of the biotechnology company’s stock worth $2,253,000 after purchasing an additional 202 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 5.0% in the first quarter. Nisa Investment Advisors LLC now owns 4,572 shares of the biotechnology company’s stock worth $323,000 after purchasing an additional 217 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN opened at $53.57 on Friday. The company has a current ratio of 4.83, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $10.29 billion, a price-to-earnings ratio of 20.14, a PEG ratio of 0.68 and a beta of 0.33. The stock has a 50 day moving average of $54.78 and a 200 day moving average of $57.07. BioMarin Pharmaceutical Inc. has a 12 month low of $51.00 and a 12 month high of $73.51.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BMRN. Weiss Ratings reissued a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, October 8th. Wall Street Zen downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday. JPMorgan Chase & Co. increased their price objective on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Raymond James Financial began coverage on BioMarin Pharmaceutical in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $85.00 price objective for the company. Finally, Barclays lowered their price objective on BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating for the company in a research note on Tuesday, October 28th. Sixteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $90.70.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.